<DOC>
	<DOCNO>NCT00494871</DOCNO>
	<brief_summary>This clinical study evaluate efficacy safety rivaroxaban stroke prevention patient atrial fibrillation ( originally describe Japanese ) .</brief_summary>
	<brief_title>Efficacy Safety Rivaroxaban Prevention Stroke Subjects With Non-Valvular Atrial Fibrillation</brief_title>
	<detailed_description>Within US 'Johnson &amp; Johnson Pharmaceutical Research &amp; Development , L.L.C . ' sponsor .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>20 year old Japanese male female Non valvular atrial fibrillation document ECG Patients risk stroke nonCNS systemic embolism Significant mitral stenosis Patients anticoagulant contraindicate</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>BAY59-7939</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Non-Valvular Atrial Fibrillation</keyword>
	<keyword>Japanese Patients</keyword>
	<keyword>Phase III</keyword>
	<keyword>12620</keyword>
</DOC>